The FDA re­fus­es to lift a clin­i­cal hold on Cel-Sci’s PhI­II drug

Pen­ny stock biotech, Cel-Sci, re­mains in the FDA’s dog house.

Last fall, the biotech re­port­ed that the FDA had put their Phase III study for Mul­ti­kine on par­tial hold. This morn­ing, the com­pa­ny re­port­ed that the FDA had up­grad­ed that to a full hold, and the biotech out­lined some of the re­main­ing is­sues that con­tin­ued to keep the clamp on.

That shift from par­tial to full hold, the com­pa­ny notes, won’t make much dif­fer­ence be­cause dos­ing has end­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER